194 related articles for article (PubMed ID: 35974345)
1. Possible significance of degeneration and decreased expression of progesterone receptor in postmenopausal uterine leiomyoma.
Tanioka S; Asano R; Wakabayashi R; Hayashi H; Shigeta H
BMC Womens Health; 2022 Aug; 22(1):346. PubMed ID: 35974345
[TBL] [Abstract][Full Text] [Related]
2. Significance of postmenopausal uterine leiomyomas: Focus on variants.
Oi Y; Katayama K; Hirata G; Ishidera Y; Yoshida H; Shigeta H
J Obstet Gynaecol Res; 2018 Aug; 44(8):1445-1450. PubMed ID: 29845685
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional analysis of steroid hormone receptors in smooth muscle uterine leiomyoma tumors of postmenopausal patients.
Strissel PL; Swiatek J; Oppelt P; Renner SP; Beckmann MW; Strick R
J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):42-7. PubMed ID: 17646097
[TBL] [Abstract][Full Text] [Related]
4. Assessment of morphological changes and steroid receptors in the uteri of postmenopausal women.
Teresiński L; Sipak O; Rył A; Masiuk M; Rotter I; Ratajczak W; Łazowska M; Słomczyńska M; Marchlewicz M; Karakiewicz B; Kram A; Laszczyńska M
Histol Histopathol; 2019 Jun; 34(6):631-644. PubMed ID: 30426467
[TBL] [Abstract][Full Text] [Related]
5. The nonrandom regional distribution of uterine leiomyomas: a clue to histogenesis?
Cramer SF; Patel A
Hum Pathol; 1992 Jun; 23(6):635-8. PubMed ID: 1592385
[TBL] [Abstract][Full Text] [Related]
6. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.
Moravek MB; Yin P; Ono M; Coon JS; Dyson MT; Navarro A; Marsh EE; Chakravarti D; Kim JJ; Wei JJ; Bulun SE
Hum Reprod Update; 2015; 21(1):1-12. PubMed ID: 25205766
[TBL] [Abstract][Full Text] [Related]
7. Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment.
Wu X; Blanck A; Olovsson M; Möller B; Lindblom B
Acta Obstet Gynecol Scand; 2001 Jun; 80(6):497-504. PubMed ID: 11380284
[TBL] [Abstract][Full Text] [Related]
8. Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas.
Uemura T; Mori J; Yoshimura Y; Minaguchi H
Asia Oceania J Obstet Gynaecol; 1991 Dec; 17(4):315-20. PubMed ID: 1724899
[TBL] [Abstract][Full Text] [Related]
9. Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells.
Sant'Anna GDS; Brum IS; Branchini G; Pizzolato LS; Capp E; Corleta HVE
Gynecol Endocrinol; 2017 Aug; 33(8):629-633. PubMed ID: 28300476
[TBL] [Abstract][Full Text] [Related]
10. Versican Proteolysis by ADAMTS Proteases and Its Influence on Sex Steroid Receptor Expression in Uterine Leiomyoma.
Gueye NA; Mead TJ; Koch CD; Biscotti CV; Falcone T; Apte SS
J Clin Endocrinol Metab; 2017 May; 102(5):1631-1641. PubMed ID: 28323982
[TBL] [Abstract][Full Text] [Related]
11. Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels.
Amant F; Huys E; Geurts-Moespot A; Lindeque BG; Vergote I; Sweep F; Schoenmakers EF
J Soc Gynecol Investig; 2003 Feb; 10(2):105-9. PubMed ID: 12594000
[TBL] [Abstract][Full Text] [Related]
12. RU486 suppresses prolactin production in explant cultures of leiomyoma and myometrium.
Stewart EA; Austin DJ; Jain P; Penglase MD; Nowak RA
Fertil Steril; 1996 Jun; 65(6):1119-24. PubMed ID: 8641483
[TBL] [Abstract][Full Text] [Related]
13. [Uterine leiomyoma: pathogenesis and treatment].
Fujii S
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Aug; 44(8):994-9. PubMed ID: 1402231
[TBL] [Abstract][Full Text] [Related]
14. Estrogen and progesterone receptors in uterine leiomyomas.
Marugo M; Centonze M; Bernasconi D; Fazzuoli L; Berta S; Giordano G
Acta Obstet Gynecol Scand; 1989; 68(8):731-5. PubMed ID: 2631544
[TBL] [Abstract][Full Text] [Related]
15. Uterine Leiomyoma Stem Cells: Linking Progesterone to Growth.
Bulun SE; Moravek MB; Yin P; Ono M; Coon JS; Dyson MT; Navarro A; Marsh EE; Zhao H; Maruyama T; Chakravarti D; Kim JJ; Wei JJ
Semin Reprod Med; 2015 Sep; 33(5):357-65. PubMed ID: 26251118
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Lombardi G; Cimini V; Zullo F
Fertil Steril; 2005 Jul; 84(1):154-61. PubMed ID: 16009171
[TBL] [Abstract][Full Text] [Related]
18. Bleeding associated with uterine leiomyomas. Tailor treatment to the individual patient.
Prescrire Int; 2014 May; 23(149):130-5. PubMed ID: 24926520
[TBL] [Abstract][Full Text] [Related]
19. The relation of fibrous degeneration to menopausal status in small uterine leiomyomas with evidence for postmenopausal origin of seedling myomas.
Cramer SF; Horiszny J; Patel A; Sigrist S
Mod Pathol; 1996 Jul; 9(7):774-80. PubMed ID: 8832561
[TBL] [Abstract][Full Text] [Related]
20. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
